A case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptor

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2256-2264

  Villegas Ruíz, Vanessa ^a   Salcedo, Mauricio ^a   Zentella Dehesa, Alejandro ^c,d   Montes de Oca, Edén V ^d   Román Basaure, Edgar ^e   Mantilla Morales, Alejandra ^f   Dávila Borja, Víctor M ^b   Juárez Méndez, Sergio ^b  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e General Hospital of México O D   (Mexico)

^f INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Alternative splicing; Cervical cancer; Expression; HMMR

Indexed keywords

HERMES ANTIGEN; HYALURONAN-MEDIATED MOTILITY RECEPTOR; MESSENGER RNA; SCLEROPROTEIN;

ALTERNATIVE RNA SPLICING; CASE REPORT; DNA SEQUENCE; EXON; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX TUMOR;

ALTERNATIVE SPLICING; ANTIGENS, CD44; BASE SEQUENCE; EXONS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 84902491121     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ortega-Cervantes L, Rojas-Garcia AE, Robledo-Marenco Mde L, Barron-Vivanco BS, Giron-Perez MI, Vallejo-Ruiz V, Lopez-Flores JF, Carrillo-Cortez A, Cantu-De Leon D, Rodriguez-Trejo A and Medina-Diaz IM. Morbidity of breast cancer and cervico-uterine cancer in women from the occidental region of Mexico. Rev Invest Clin 2013; 65: 221-227.
2. Moody CA and Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-560.
3. Li H, Fan X and Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007; 101: 805-815.
4. Modrek B, Resch A, Grasso C and Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001; 29: 2850-2859.
5. Akgul C, Moulding DA and Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004; 61: 2189-2199.
6. Bonomi S, Gallo S, Catillo M, Pignataro D, Biamonti G and Ghigna C. Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol 2013; 2013: 962038.
7. Adamia S, Reiman T, Crainie M, Mant MJ, Belch AR and Pilarski LM. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood 2005; 105: 4836-4844.
8. Cheng C and Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol 2006; 26: 362-370.
9. Toole BP. Hyaluronan and its binding proteins, the hyaladherins. Curr Opin Cell Biol 1990; 2: 839-844.
10. Assmann V, Jenkinson D, Marshall JF and Hart IR. The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. J Cell Sci 1999; 112: 3943-3954.
11. Crainie M, Belch AR, Mant MJ and Pilarski LM. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 1999; 93: 1684-1696.
12. Lynn BD, Turley EA and Nagy JI. Subcellular distribution, calmodulin interaction, and mitochondrial association of the hyaluronan-binding protein RHAMM in rat brain. J Neurosci Res 2001; 65: 6-16.
13. Entwistle J, Hall CL and Turley EA. HA receptors: regulators of signalling to the cytoskeleton. J Cell Biochem 1996; 61: 569-577.
14. Golshani R, Lopez L, Estrella V, Kramer M, Iida N and Lokeshwar VB. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 2008; 68: 483-491.
15. Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, Kawakubo M, Kannagi R, Kimata K, Taniguchi S and Itano N. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol 2007; 170: 1086-1099.
16. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J and Turley EA. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007; 282: 16667-16680.
17. Ishigami S, Ueno S, Nishizono Y, Matsumoto M, Kurahara H, Arigami T, Uchikado Y, Setoyama T, Arima H, Yoshiaki K, Kijima Y, Kitazono M and Natsugoe S. Prognostic impact of CD168 expression in gastric cancer. BMC Cancer 2011; 11: 106.
18. Yamano Y, Uzawa K, Shinozuka K, Fushimi K, Ishigami T, Nomura H, Ogawara K, Shiiba M, Yokoe H and Tanzawa H. Hyaluronan-mediated motility: a target in oral squamous cell carcinoma. Int J Oncol 2008; 32: 1001-1009.
19. Terris MK and Peehl DM. Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology 1997; 50: 150-156.
20. Juarez-Mendez S, Zentella A, Villegas-Ruiz V, Perez-Gonzalez OA, Salcedo M, Lopez-Romero R, Roman-Basaure E, Lazos-Ochoa M, Montes de Oca-Fuentes VE, Vazquez-Ortiz G and Moreno J. Splice variants of zinc finger protein 695 mRNA associated to ovarian cancer. J Ovarian Res 2013; 6: 61.
21. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009; 384: 260-265.
22. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
23. Faustino NA and Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003; 17: 419-437.
24. Garcia-Blanco MA, Baraniak AP and Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004; 22: 535-546.
25. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 2000; 25: 106-110.
26. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G and Baralle FE. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987; 6: 2337-2342.
27. Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J and Der CJ. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 2004; 23: 9369-9380.
28. Carninci P. Constructing the landscape of the mammalian transcriptome. J Exp Biol 2007; 210: 1497-1506.
29. Missler M and Sudhof TC. Neurexins: three genes and 1001 products. Trends Genet 1998; 14: 20-26.
30. Joseph R, Dou D and Tsang W. Neuronatin mRNA: alternatively spliced forms of a novel brain-specific mammalian developmental gene. Brain Res 1995; 690: 92-98.
31. Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S and Eymin B. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 2010; 29: 5392-5403.
32. Guo M, Liu W, Serra S, Asa SL and Ezzat S. FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. Cancer Res 2012; 72: 2017-2027.
33. Toole BP, Munaim SI, Welles S and Knudson CB. Hyaluronate-cell interactions and growth factor regulation of hyaluronate synthesis during limb development. Ciba Found Symp 1989; 143: 138-145; discussion 145-139 281-135.
34. Toole BP. Developmental role of hyaluronate. Connect Tissue Res 1982; 10: 93-100.
35. Goldberg RL, Seidman JD, Chi-Rosso G and Toole BP. Endogenous hyaluronate-cell surface interactions in 3T3 and simian virus-transformed 3T3 cells. J Biol Chem 1984; 259: 9440-9446.
36. Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, Savani RC and Kumar S. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 2007; 26: 58-68.
37. Park D, Kim Y, Kim H, Kim K, Lee YS, Choe J, Hahn JH, Lee H, Jeon J, Choi C, Kim YM and Jeoung D. Hyaluronic acid promotes angiogenesis by inducing RHAMM-TGFbeta receptor interaction via CD44-PKCdelta. Mol Cells 2012; 33: 563-574.
38. Turley EA, Austen L, Vandeligt K and Clary C. Hyaluronan and a cell-associated hyaluronan binding protein regulate the locomotion of ras-transformed cells. J Cell Biol 1991; 112: 1041-1047.
39. Bourguignon LY. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 2008; 18: 251-259.
40. Hatano H, Shigeishi H, Kudo Y, Higashikawa K, Tobiume K, Takata T and Kamata N. Overexpression of receptor for hyaluronan-mediated motility (RHAMM) in MC3T3-E1 cells induces proliferation and differentiation through phosphorylation of ERK1/2. J Bone Miner Metab 2012; 30: 293-303.
41. Maxwell CA, Benítez J, Gómez-Baldó L, Osorio A, Bonifaci N, Fernández-Ramires R, Costes SV, Guinó E, Chen H, Evans GJ, Mohan P, Català I, Petit A, Aguilar H, Villanueva A, Aytes A, Serra-Musach J, Rennert G, Lejbkowicz F, Peterlongo P, Manoukian S, Peissel B, Ripamonti CB, Bonanni B, Viel A, Allavena A, Bernard L, Radice P, Friedman E, Kaufman B, Laitman Y, Dubrovsky M, Milgrom R, Jakubowska A, Cybulski C, Gorski B, Jaworska K, Durda K, Sukiennicki G, Lubiński J, Shugart YY, Domchek SM, Letrero R, Weber BL, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, Roozendaal CE; HEBON; EMBRACE, Easton DF, Peock S, Cook M, Oliver C, Frost D, Harrington P, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Eccles D, Douglas F, Brewer C, Nevanlinna H, Heikkinen T, Couch FJ, Lindor NM, Wang X, Godwin AK, Caligo MA, Lombardi G, Loman N, Karlsson P, Ehrencrona H, Wachenfeldt Av; SWE-BRCA, Barkardottir RB, Hamann U, Rashid MU, Lasa A, Caldés T, Andrés R, Schmitt M, Assmann V, Stevens K, Offit K, Curado J, Tilgner H, Guigó R, Aiza G, Brunet J, Castellsagué J, Martrat G, Urruticoechea A, Blanco I, Tihomirova L, Goldgar DE, Buys S, John EM, Miron A, Southey M, Daly MB; BCFR, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Deissler H, Varon-Mateeva R, Sutter C, Niederacher D, Imyamitov E, Sinilnikova OM, Stoppa-Lyonne D, Mazoyer S, Verny-Pierre C, Castera L, de Pauw A, Bignon YJ, Uhrhammer N, Peyrat JP, Vennin P, Fert Ferrer S, Collonge-Rame MA, Mortemousque I; GEMO Study Collaborators, Spurdle AB, Beesley J, Chen X, Healey S; kConFab, Barcellos-Hoff MH, Vidal M, Gruber SB, Lázaro C, Capellá G, McGuffog L, Nathanson KL, Antoniou AC, Chenevix-Trench G, Fleisch MC, Moreno V, Pujana MA. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol 2011; 9: e1001199.
42. Mohan P, Castellsague J, Jiang J, Allen K, Chen H, Nemirovsky O, Spyra M, Hu K, Kluwe L, Pujana MA, Villanueva A, Mautner VF, Keats JJ, Dunn SE, Lazaro C and Maxwell CA. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. Oncotarget 2013; 4: 80-93.
43. Tzankov A, Strasser U, Dirnhofer S, Menter T, Arber C, Jotterand M, Rovo A, Tichelli A, Stauder R and Gunthert U. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. Ann Hematol 2011; 90: 901-909.
44. Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R and Ringhoffer M. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009; 11: 956-963.